- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
Vol. 3, No. 2
Summer 2013
The Summer 2013 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
Relevant court decisions highlighted in this issue:
- FTC v. Actavis, Inc.
- Novo Nordisk A/S v. Caraco Pharma. Labs., Ltd.
- Dey, L.P. v. Sunovion Pharma., Inc.
Read more about these and other important court decisions, New ANDA Cases, ANDA Litigation Settlements, ANDA Approvals, and Generic Launches.
Related Professionals
Defendant is able to defeat a summary-judgment motion of no inequitable conduct given the lesser burden than having to prove inequitable conduct at trial, and the court's finding that reasonable trier of fact could conclude that patentees withheld material information from USPTO.
Granting plaintiffs' motions seeking a permanent injunction after finding that the patents were valid and infringed.
Appellate court reversed in part district court's finding of non-obviousness when prior art taught claimed combination drug.
First patent-in-suit found infringed, but invalid as obvious and anticipated; second patent-in-suit not infringed as a result of court's claim construction of "micronized powder composition."
Reversing and remanding the case finding that the district court misconstrued the term "substantially pure."
Appellate court reversed finding of validity after prior art (i) found to disclose not only hormonal replacement therapy, but also contraceptive applications, and (ii) taken as a whole, did not teach away from claimed invention.
As a result of credibility findings pertaining to the parties' respective expert witnesses, court held patent-in-suit not invalid.
Clinical trial was not "public use" under 102(b), therefore summary judgment of invalidity was reversed.
Reverse-payment settlement agreements may sometimes violate antitrust laws and a rule-of-reason approach guided by antitrust principles should apply.
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
Finding of obviousness affirmed because patentee could not "overcome" prima facie obviousness with evidence of unexpected results, and finding of unenforceability reversed because omissions, although "troubling," were not material.
Patent-in-suit not invalid, particularly in view of the same or similar arguments being raised, and rejected, in previous actions.
Finding expert's testing and testimony credible, court finds ANDA product infringes melting point claim limitations and rejects lack of written description and non-enablement invalidity arguments.
There is no requirement under the Hatch-Waxman Act that a patent must be listed in the Orange Book in order for a drug manufacturer to bring an infringement action.
Patent-in-suit infringed as a result of meeting particle size limitation as evidenced by expert testing and favorable claim construction; patent-in-suit not invalid given expert witness credibility finding and knowledge of person of ordinary skill.
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.